AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$DHR

Blair Rainer sold $12.7M of DHR (indirect holdings)

Blair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Blair Rainer
Published Aug 24, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DHR
Bearish
medium confidence
Mentioned
$DHR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

The sale reduces insider ownership to zero, potentially affecting investor perception of confidence.

02

Market read

Direct impact on DHR stock; limited broader market effect.

03

What to watch

No 10b5‑1 plan; sale may be tax‑driven or personal liquidity need.

Relevance 7/10Novelty 7/10Timing: filing released on 2026-08-24

Background

Form 4 filings disclose insider transactions; large executive sales are closely watched.

Company-level read

Ticker impact

$DHRBearishMedium confidence
Context

President & CEO Blair Rainer sold 58,255 shares for $12.7M, reducing his stake to zero.

Expected impact

Potential short-term dip of 1-2% as market digests the sale.

Evidence & confidence

Sale size is material for a large-cap; insider is top executive, but no pre‑arranged plan disclosed.

Market effects

Sector

May prompt scrutiny of Danaher governance but limited sector impact.

Regional

U.S. market focus; no broader regional effect.

Global

Minimal global relevance beyond Danaher investors.

Counterpoint

What could challenge this read

Insider sell could be routine diversification, not a negative signal.

Key entities

  • Executive
    Blair Rainer

    President & CEO of Danaher Corp.

  • Company
    Danaher Corp.

    Global science and technology conglomerate.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DHR insider trading history →

Related articles

OCT 22
$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.

investing.com2 min
OCT 22
$DHRMed

Stifel maintains Buy rating on Danaher, $260 price target

Stifel maintained a Buy rating on Danaher with a $260 price target, suggesting 11.2% upside from the Oct 21 close. The firm cited strong financial performance, including 8.5% revenue growth and a 29.0% adjusted operating profit margin, as well as positive growth prospects under new leadership.

tradingview.com1 min
OCT 22
$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

finance.yahoo.com1 min
OCT 22
$DHRHighAI 9/10

DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook

Danaher (DHR) reported Q3 revenue of $6.55B, matching estimates, and adjusted EPS of $2.11, beating forecasts. The company raised its full-year EPS guidance to $8.59. Organic revenue grew 3%, driven by strong demand in bioprocessing and diagnostics. Management highlighted AI strategy, M&A integration, and market recovery trends. Risks include variability in respiratory-related revenue and bioprocessing projects.

finance.yahoo.com2 min